Skip to content
lsd.com
Active, not recruitingPhase 3

A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

NCT06741228 · Definium Therapeutics US, Inc.

Closed to entry
Status
Not accepting participants
Phase 3
Phase
214
Target enrolment
34
Study sites
18 US states

What it is testing

Summary

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12

    Measured over Baseline to Week 12

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 74 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: 1. Diagnosis of GAD per DSM-5 2. Male or female aged 18 to 74 3. HAM-A Total Score ≥20 Exclusion Criteria: 1. Certain psychiatric disorders (other than generalized anxiety disorder) 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine) 4. Any clinically significant unstable illness

Where

34 study sites

FacilityCityRegionCountry
Lighthouse PsychiatryGilbertArizonaUnited States
Scottsdale Research InstituteScottsdaleArizonaUnited States
Kadima Neuropsychiatry InstituteLa JollaCaliforniaUnited States
UCSF Department of NeurologySan FranciscoCaliforniaUnited States
Psychedelic Science InstituteSanta MonicaCaliforniaUnited States
Mountain ViewDenverColoradoUnited States
Clinical Neuroscience Solutions Inc.JacksonvilleFloridaUnited States
Segal TrialsLauderhillFloridaUnited States
Atlanta Center for Medical ResearchAtlantaGeorgiaUnited States
iResearch AtlantaDecaturGeorgiaUnited States
CenExel iResearch, LLCSavannahGeorgiaUnited States
Uptown Research InstituteChicagoIllinoisUnited States
Adams Clinical BostonBostonMassachusettsUnited States
Adams Clinical WatertownWatertownMassachusettsUnited States
Hassman Research InstituteMarltonNew JerseyUnited States
Spectrum Neuroscience and Treatment InstituteNew YorkNew YorkUnited States
Adams Clinical HarlemNew YorkNew YorkUnited States
New York State Psychiatric Institute (NYSPI)New YorkNew YorkUnited States
Adams Clinical BronxThe BronxNew YorkUnited States
Cleveland Clinic Lutheran HospitalClevelandOhioUnited States
Summit Headlands LLCPortlandOregonUnited States
Scranton Medical InstituteMoosicPennsylvaniaUnited States
Adams Clinical PhiladelphiaPhiladelphiaPennsylvaniaUnited States
Coastal Carolina Research CenterNorth CharlestonSouth CarolinaUnited States
Clinical Neuroscience Solutions, Inc.MemphisTennesseeUnited States
University of Texas at AustinAustinTexasUnited States
Austin Clinical Trial PartnersAustinTexasUnited States
BioBehavioral Research of AustinAustinTexasUnited States
FutureSearch Trials of Dallas, LLCDallasTexasUnited States
Adams Clinical DallasDeSotoTexasUnited States
Cedar Clinical ResearchDraperUtahUnited States
Inner Space ResearchOremUtahUnited States
Memory Clinic Inc.BenningtonVermontUnited States
Seattle Neuropsychiatric Treatment CenterSeattleWashingtonUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT06741228 on ClinicalTrials.gov →

Last updated in the registry 2026-06-22. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

All 7 trials from Definium Therapeutics US, Inc. →